HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Menstrual and hormonal alterations in juvenile systemic lupus erythematosus.

Abstract
Menstrual cycles of 30 patients with juvenile systemic lupus erythematosus (JSLE) were compared with 30 age-matched controls. The mean age of patients with JSLE and controls was similar (17.4 +/- 3.2 vs 17.06 +/- 2.08 years, P = 0.66). The mean menarche age was higher in JSLE than controls (13.13 +/- 1.4 vs 11.56 +/- 1.5 years, P = 0.0008). On the contrary, the mean maternal menarche age was similar in both groups (P = 0.62). Menstrual abnormalities and longer length cycles were more frequently observed in JSLE than controls (63% vs 10%, P = 0.0001; 23% vs 0%, P = 0.0105, respectively). The median of follicle stimulating hormone was significantly higher in patients with JSLE compared with controls (4.6 vs 3.4 IU/L, P = 0.0207), and the median of progesterone was lower (32.5 vs 70 ng/mL, P = 0.0033). The median of luteinizing hormone was lower in patients with JSLE with menstrual abnormalities versus normal cycles (2.9 vs 5.5 IU/L, P = 0.019) and both had a high percentage of decreased progesterone levels (63% vs 73%, P = 0.70). Our findings support the notion that menstrual disturbances are frequent and may be associated with pituitary dysfunction leading to a decreased progesterone production. We also reported that in spite of premature ovarian failure being a rare event in JSLE the follicular reserve seems to be low regardless of intravenous cyclophosphamide treatment.
AuthorsP B Medeiros, M V Febrônio, E Bonfá, E F Borba, A D Takiuti, C A A Silva
JournalLupus (Lupus) Vol. 18 Issue 1 Pg. 38-43 (Jan 2009) ISSN: 0961-2033 [Print] England
PMID19074167 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Immunosuppressive Agents
  • Progesterone
  • Cyclophosphamide
  • Luteinizing Hormone
  • Follicle Stimulating Hormone
Topics
  • Adolescent
  • Brazil (epidemiology)
  • Case-Control Studies
  • Child
  • Cyclophosphamide (therapeutic use)
  • Female
  • Follicle Stimulating Hormone (blood)
  • Humans
  • Immunosuppressive Agents (therapeutic use)
  • Lupus Erythematosus, Systemic (physiopathology)
  • Luteinizing Hormone (blood)
  • Menarche (physiology)
  • Menstrual Cycle (metabolism)
  • Pituitary Diseases (etiology, physiopathology)
  • Progesterone (blood)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: